In recent years, the bile duct cancer market is anticipated to grow rapidly during the forecast period. Bile duct carcinoma is a rare disease that can affect both the inside and outside of the liver (intrahepatic and extrahepatic) (extrahepatic). The number of reported cases is lower. However, the overall rate of development appears to be higher, as numerous cancer patients are misdiagnosed with other cancers. According to the American Cancer Society, the condition is particularly common in Southeast Asian countries due to parasite infection, which can develop cancer in the bile duct region of the human body.
Frequently Asked Questions
The market is segmented based on Segmentation, By Product (5-fluorouracil (5-FU), Gemcitabine, Cisplatin, Capecitabine, Oxaliplatin), Application (Hospitals, Clinics, Others), Disease Indication (Intrahepatic Bile Duct Cancer, Extrahepatic Bile Duct Cancer), Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies) – Industry Trends and Forecast to 2031.
.
The Global Bile Duct Cancer Market size was valued at USD 214.25 USD Million in 2023.
The Global Bile Duct Cancer Market is projected to grow at a CAGR of 7.5% during the forecast period of 2024 to 2031.
The major players operating in the market include Johnson & Johnson Private Limited, Mylan N.V., Teva Pharmaceutical Industries , Sanofi, Pfizer , GlaxoSmithKline plc, AbbVie , Novartis AG, Fresenius Kabi AG, Eli Lilly and Company, F. Hoffmann-La Roche , Intercept Pharmaceuticals, Kyowa Kirin Co. , Delcath Systems , Accord Healthcare, CONMED Corporation, Boston Scientific Corporation, Bayer AG, Bristol-Myers Squibb Company, Merck & Co. .
The market report covers data from the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
